Vaccines

11 Dec 2019 GemVax announced phase II results of GV1001 for Alzheimer's disease treatment at CTAD 2019
10 Dec 2019 Emergex Successfully Completes Preclinical Testing of its Lead ‘Set-Point’ Vaccine Candidate for Dengue Fever and Other Flaviviruses
09 Dec 2019 Nouscom - First Patient Dosed in a Phase 1 Trial With NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine, in MSI-High Solid Tumors
06 Dec 2019 Meissa Vaccines Receives FDA Clearance of IND Application for a Phase 1 Clinical Trial of MV-012-968 for Respiratory Syncytial Virus
05 Dec 2019 Osivax Enters Agreement with U.S. National Institutes of Health to Test Universal Flu Vaccine Candidate
04 Dec 2019 Advaxis Announces Submission of IND Application for ADXS-HOT Drug Candidate for Prostate Cancer
26 Nov 2019 Prokarium announces MHRA acceptance to run Phase I trial of lead vaccine against enteric fever
26 Nov 2019 Vaccitech Provides Update on Clinical Progress for its Two Phase 2 Universal Influenza Studies
24 Nov 2019 Takeda Presents 18-Month Data from Pivotal Phase 3 Trial of Dengue Vaccine Candidate at the American Society of Tropical Medicine and Hygiene (ASTMH) 68th Annual Meeting
23 Nov 2019 Emergent BioSolutions Presents Positive Immunogenicity Results From Phase 2 Study of Its Investigational Chikungunya VLP Vaccine Candidate
22 Nov 2019 Elios Therapeutics Presents Primary Analysis of Phase IIb Study Showing Personalized Cancer Vaccine Significantly Reduces Risk of Melanoma Recurrence in High-Risk Patients
22 Nov 2019 VBI Vaccines Presents Early GBM Tumor Response and Immunologic Data from Part B of Ongoing Phase 1/2a Study of VBI-1901 at the 2019 SNO Annual Meeting
19 Nov 2019 Enrollment and Randomization of 12,463 Participants Complete in BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine trial
18 Nov 2019 Valneva Reports Excellent Final Phase 1 Results for its Chikungunya Vaccine Candidate, Confirms Plans
14 Nov 2019 VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B Infection
12 Nov 2019 NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines
12 Nov 2019 Merck’s ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union
11 Nov 2019 OSE Immunotherapeutics Presented Positive Correlation Between Neoepitope Response and Increased Survival for NSCLC Patients Treated with Tedopi®
09 Nov 2019 Neon Therapeutics Announces Updated Data Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting
08 Nov 2019 Boston Biomedical, Inc. Highlights Phase 1 Data Evaluating Investigational WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S*) in Patients with Advanced Malignancies at SITC 2019
08 Nov 2019 Immutep presents positive interim data from phase II TACTI-002 trial at SITC
08 Nov 2019 Johnson & Johnson Announces Submission of European Marketing Authorisation Applications for Janssen’s Investigational Ebola Vaccine Regimen
07 Nov 2019 Takeda’s Dengue Vaccine Candidate Demonstrates Protection in Children Ages Four to 16 Years, Regardless of Previous Dengue Exposure
06 Nov 2019 Heat Biologics Reports Positive Phase 2 Interim Data in NSCLC Patients Who Previously Failed Checkpoint Inhibitor Treatment
06 Nov 2019 Inovio demonstrates 80% 6-month progression-free survival in Phase 2 glioblastoma multiforme (GBM) study

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top